By performing univariate and multivariate analyses, this biomarker outperformed BNP in predicting CV-related mortality in corticosteroid-treated subjects with CS, thereby identifying a subgroup potentially resistant to treatment (urinary concentration > 19.1 ng/mg·Cr with P = 0.001) [44]. This evidence concerns the gene NPPB and Cowden syndrome 1.